Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2015-09-18

FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)

View source ↗

Summary

FDA approved a supplemental application for Sabril (vigabatrin) filed by Lundbeck Pharmaceuticals LLC, resulting in updated labeling for the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SABRIL (VIGABATRIN)

Snippet

SUPPL AP for SABRIL (VIGABATRIN)